A. Spada

J. Chan, A. Spada, M. Fallon, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa.

C. Dunwiddie, R. Bentley, A. Spada, 1999, Journal of cardiovascular pharmacology.

RPR120844, a Novel, Specific Inhibitor of Coagulation Factor Xa Inhibits Venous Thrombosis in the Rabbit

C. Dunwiddie, R. Bentley, A. Spada, 1999, Thrombosis and Haemostasis.

Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.

A. Spada, D. Colussi, Y. Gong, 2000, Bioorganic & medicinal chemistry letters.

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent.

M. Myers, Wei He, N. Setzer, 2003, Bioorganic & medicinal chemistry letters.

Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.

Robert Leadley, Guyan Liang, R. Bentley, 2003, Journal of medicinal chemistry.

Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA.

C. Dunwiddie, D. Cheney, R. Bentley, 1999, Bioorganic & medicinal chemistry letters.

Crystal structures of human factor Xa complexed with potent inhibitors.

A. Spada, W. R. Ewing, V. Mikol, 2000, Journal of medicinal chemistry.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.

D L Cheney, C. Dunwiddie, J. Mason, 1999, Journal of medicinal chemistry.

Nonbenzamidine compounds as selective factor Xa inhibitors.

M. Myers, A. Spada, D. Colussi, 2000, Bioorganic & medicinal chemistry letters.

Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors.

R. Bentley, A. Spada, C. Ly, 1999, Bioorganic & medicinal chemistry letters.

Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors.

M. Myers, Wei He, A. Spada, 2002, Bioorganic & Medicinal Chemistry Letters.

Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.

D L Cheney, C. Dunwiddie, D. Cheney, 1998, Journal of medicinal chemistry.

A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives.

A. Zilberstein, A. Spada, M. Maguire, 1994, Journal of medicinal chemistry.

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor.

M. Myers, Wei He, A. Spada, 2003, Bioorganic & medicinal chemistry letters.

Photochemistry of 4-hydroxypyrylium cations in aqueous sulfuric acid

A. Spada, J. Pavlik, T. Snead, 1985 .

Photo-ring contraction reactions of 4-hydroxypyrylium cations

A. Spada, J. Pavlik, 1980 .

trans‐1,2‐Bis(tributylstannyl)ethylene

A. Spada, 2001 .

Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.

C. Dunwiddie, D. Cheney, R. Bentley, 1999, Journal of medicinal chemistry.

Singlet oxygen in synthesis. Oxazoles as carbonyl 1,1-dipole synthons.

A. Spada, H. Wasserman, K. E. Mccarthy, 1992 .

Tri‐n‐butylstannylacetylene

A. Spada, 2001 .

Synthesis of trichoverrol B

A. Spada, W. Roush, 1983 .

Enantio- and stereoselective syntheses of the dihydroxyoctadienoic acid framents of the roridins and trichoverrins

A. Spada, W. Roush, 1982 .

Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice.

A. Spada, R. Elbekai, P. Contreras, 2015, Regulatory toxicology and pharmacology : RTP.

(E)‐3‐Tributylstannyl‐2‐propenyl 2‐Tetrahydropyranyl Ether

A. Spada, 2001 .

Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.

Sébastien Maignan, William R Ewing, A. Spada, 2003, Journal of medicinal chemistry.

Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID

M. Latterich, A. Spada, M. Corley, 2021, Allergy.

A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.

R. Jalan, A. Spada, G. Burgess, 2017, Journal of clinical and experimental hepatology.

Conformational restrictions in the active site of unliganded human caspase‐3

C. Ni, K. R. Ely, Chenglong Li, 2003, Journal of molecular recognition : JMR.

Structural and functional analysis of caspase active sites.

A. Spada, K. Tomaselli, Joe C. Wu, 2003, Biochemistry.

Benzimidazoles and Isosteric Compounds as Potent and Selective Factor Xa Inhibitors

M. Myers, Wei He, A. Spada, 2002 .

Stent-induced Restenosis in the Swine Coronary Artery Is Inhibited by a Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, TKI963

Wei He, A. Spada, M. McVey, 2003, Journal of cardiovascular pharmacology.

Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A.

C. Dunwiddie, A. Spada, P. Persons, 1999, Circulation.

Induction of heat shock protein 70 by herbimycin A and cyclopentenone prostaglandins in smooth muscle cells

A. Zilberstein, A. Spada, A. Ardati, 2000, Cell stress & chaperones.

Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation

Y. Koyama, A. Wree, A. Spada, 2018, Journal of Molecular Medicine.

Caspases in COVID-19 Disease and Sequela and the Therapeutic Potential of Caspase Inhibitors

M. Latterich, A. Spada, M. Corley, 2020, medRxiv.

The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice.

M. M. Alsina, A. Zilberstein, T. Yoneda, 1991, Cancer research.

The Potent Pan-Caspase Inhibitor IDN-7314 Does Not Affect Tumor Growth Rate nor Does it Antagonize the Efficacy of Sorafenib in Models of Hepatocellular Carcinoma

A. Spada, P. Contreras, 2016 .

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.

Daniel L Cheney, C. Dunwiddie, D. Cheney, 2002, Bioorganic & medicinal chemistry letters.